Yahoo Finance

Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR ...

- Oral presentation to feature new data highlighting the potential of zocilurtatug pelitecan (formerly called ZL-1310) as a promising next-generation, first- and best-in-class, Delta-like ligand (DLL3 ...
Healio

Ophthalmology News

Use of GLP-1 receptor agonists was associated with a twofold higher risk for neovascular age-related macular degeneration development in a population-based study published in JAMA Ophthalmology. A ...
Investopedia

Commerce vs. Business and Trade: Understanding the Differences

Michael Boyle is an experienced financial professional with more than 10 years working with financial planning, derivatives, equities, fixed income, project management, and analytics. Amanda Jackson ...
BioSpace

BlossomHill Therapeutics Announces Upcoming Poster Presentation on Phase 1/2 SOLARA Trial of BH-30643, a First-in-class, Macrocyclic OMNI-EGFR™ Inhibitor, at the AACR-NCI ...

SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, ...
C&EN

Discovery of the First-In-Class HSD17B13/PPAR Multitarget Modulators for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis

The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong Pharmaceutical University, Guangzhou 510006, PR China School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou ...